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Aims Osteopontin (OPN) is a multifunctional cytokine critically involved in cardiac fibrosis. However, the underlying mechan-
isms are unresolved. Non-coding RNAs are powerful regulators of gene expression and thus might mediate this process.
Methods
and results
OPN and miR-21 were significantly increased in cardiac biopsies of patients with myocardial fibrosis. Ang II infusion via
osmotic minipumps led to specific miRNA regulations with miR-21 being strongly induced in wild-type (WT) but not
OPN knockout (KO) mice. This was associated with enhanced cardiac collagen content, myofibroblast activation,
ERK-MAP kinase as well as AKT signalling pathwayactivationand a reduced expressionof Phosphatase and Tensin Homo-
logue (PTEN) as well as SMAD7 in WT but not OPN KO mice. In contrast, cardiotropic AAV9-mediated overexpression
of OPN in vivo further enhanced cardiac fibrosis. In vitro, Ang II induced expression of miR-21 in WT cardiac fibroblasts,
while miR-21 levels were unchanged in OPN KO fibroblasts. As pri-miR-21 was also increased by Ang II, we studied
potential involved upstream regulators; Electrophoretic Mobility Shift and Chromatin Immunoprecipitation analyses
confirmed activation of the miR-21 upstream-transcription factor AP-1 by Ang II. Recombinant OPN directly activated
miR-21, enhanced fibrosis, and activated the phosphoinositide 3-kinase pathway. Locked nucleic acid-mediated miR-21
silencing ameliorated cardiac fibrosis development in vivo.
Conclusion In cardiac fibrosis related to Ang II, miR-21 is transcriptionally activated and targets PTEN/SMAD7 resulting in increased
fibroblast survival. OPN KO animals are protected from miR-21 increase and fibrosis development due to impaired AP-1
activation and fibroblast activation.
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Translational perspective
Osteopontin (OPN) is a pleiotropic cytokine, which has been shown to be a pivotal factor in myofibroblast activation in cardiac fibrosis,
thereby acting as a strong driver of heart failure development in humans. MicroRNAs (miRNAs) are under intense investigation as powerful
regulators of various diseases. First phase I and II clinical trials using miRNA inhibitors have been initiated. We here show, that OPN is essential
in the activation of AP-1 and subsequent transcription of miR-21 in cardiac fibrosis related to Ang II. OPN null mice are protected from miR-21
increase and fibrosis development due to impaired AP-1 activation and fibroblast activation. In the future, these findings may result in miRNA
therapeutic approaches to treat patients with cardiac remodelling, in which levels of OPN and miR-21 are increased.
Introduction
Cardiac fibrosis is characterized by activation/proliferation of cardiac
fibroblasts and excessive matrix deposition, including collagen.1 It is
associated with a variety of injurious insults of different causes to
cardiac tissue, which culminates in destruction of physiological
tissue architecture and progressive organ dysfunction, ultimately
resulting in heart failure.1 A major role in this process has been attrib-
uted to various growth factors, proteolytic enzymes, angiogenic
factors, and fibrogenic cytokines.1,2 Osteopontin (OPN) is a pleio-
tropic cytokine that is involved in the recruitment and retention of
macrophages and T cells to sites of inflammation.3 It has been
shown to be a pivotal factor in myofibroblast activation in cardiac fi-
brosis,4 thereby acting as a strong driver of heart failure development
in humans.5 Classical mediators of acute inflammation [tumour ne-
crosis factor-a (TNF-a) and interleukin 1-b (IL-1b)] as well as fibro-
genic cytokines [angiotensin II (Ang II), transforming growth factor-b
(TGF-b)] strongly induce OPN expression.3 OPN has thus been
implicated as a key factor in the development of interstitial fibrosis.6,7
Moreover, OPN was identified as a strong independent predictor of
mortality in patients with chronic heart failure.8 However, the under-
lying mechanisms of OPN transcriptional regulation with regard to
fibrosis development in the heart are not well defined. MicroRNAs
(miRNAs) are under intense investigation as powerful regulators of
various diseases with potential critical impact on disease initiation
and/or progression. MiRNAs represent small non-coding RNA tran-
scripts with a length of 22 nucleotides, which through post-
transcriptional binding of the 3′-untranslated region (UTR) of
mRNA targets lead to the repression of gene/protein expression
and/or translational inhibition of protein synthesis.9 In the present
study, we analysed the transcriptional regulation of Osteopontin-
related fibrogenic miRNA expression in response to Ang II in vivo
using OPN wild-type (WT) and knockout (KO) mice as well as in
vitro in primary cardiac fibroblasts. The in vivo role of OPN was
further characterized by cardiac overexpression of OPN with
adeno-associated viral vectors of serotype 9 (AAV9). Cardiac biop-
sies of patients with myocardial fibrosis related to aortic stenosis
were analysed concerning OPN and fibrogenic miRNA expression.
Methods
Myocardial biopsies of patients
Patients with myocardial fibrosis related to aortic stenosis (n ¼ 15) as
well as healthy controls (n ¼ 5) were included for myocardial biopsies.
Patients with aortic stenosis were recruited at the Department of
Cardiology, Wu¨rzburg University. Healthy tissue was obtained from
AMS Biotechnology (USA). Patient characteristics and echocardiograph-
ic data are displayed in Table 1. The study was approved by the institution-
al review committee. Patients gave written informed consent.
Cell culture and reagents
Adult mouse cardiac fibroblasts were isolated from OPN WT and KO
mice by enzymatic digestion as described previously with modifica-
tions.10 Primary mouse cardiac fibroblasts were cultured in DMEM
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Table 1 Demographic, clinical, and laboratory
characteristics of patients
Total Male Female
Number of patients (%) 15 8 (53) 7 (47)
Age (years; mean + SD) 78 (4.3) 77 (3.7) 78 (5.2)
Concomitant disease
Arterial hypertension (n; %) 11 (73) 7 (47) 4 (27)
Diabetes mellitus (n; %) 7 (47) 5 (33) 2 (13)
Renal insufficiency (n; %) 3 (20) 2 (13) 1 (6)
Myocardial infarction (n; %) 1 (6) 0 (0) 1 (6)
Stroke (n; %) 1 (6) 1 (6) 0 (0)
Cancer (n; %) 3 (20) 1 (6) 2 (13)
Concomitant drug treatment
ARB (n; %) 5 (33) 4 (27) 1 (6)
ACE-inhibitors (n; %) 8 (53) 4 (27) 4 (27)
Beta-blocker (n; %) 9 (60) 4 (27) 5 (33)
Aldosterone antagonist (n; %) 1 (6) 0 (0) 1 (6)
Calcium channel blocker (n; %) 4 (27) 2 (13) 2 (13)
Diuretics (n; %) 11 (73) 6 (40) 5 (33)
Statins (n; %) 7 (20) 4 (27) 3 (20)
Acetylsalicylic acid (n; %) 8 (53) 4 (27) 4 (27)
Septum (mm) 12 (0.3) 13 (0.2) 12 (0.3)
Posterior wall (mm) 12 (0.3) 13 (0.3) 12 (0.2)
LVEDd (mm) 46 (0.9) 50 (1) 44 (0.6)
AOA (cm2) 0.8 (0.2) 0.9 (0.2) 0.8 (0.1)
dPmean (mmHg) 40 (1.8) 40 (1.6) 39 (2.2)
LVEF (%) 63 (1.2) 61 (1.4) 63.5 (0.9)
ACE-inhibitors, angiotensin-converting enzyme inhibitors; AOA, aortic opening
area; ARB, angiotensin-receptor blockers; dPmean, change in mean pressure;
LVEDd, left-ventricular end-diastolic diameter; n, number of patients included.
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(PAA) supplementedwith10%FBSand1%penicillin/streptomycinat378C
in 5% CO2. HL-1 cells were cultured in Claycomb Medium (Sigma-Aldrich,
St Louis, MO, USA, catalogue no. 51800C) with 10% FBS (Sigma-Aldrich,
catalogue no. 12103C), penicillin/streptomycin (100 U/mL:100 mg/mL;
Sigma-Aldrich, catalogue no. P4333), 0.1 mM norepinephrine (Sigma-
Aldrich, catalog no. A0937), 2 mM L-glutamine (Sigma-Aldrich, catalogue
no. G7513) at 378C in 5% CO2. Primary mouse cardiac fibroblasts and
HL-1 cells were grown to a confluence of 80%. The cells were starved
for 24 h in DMEM containing 1% FBS before they were stimulated with
100 nM Ang II.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was used to detect protein–
DNA interactions. We applied the MAGnifyTM Chromatin Immunopre-
cipitation System according to the manufacturer’s instructions (Life tech-
nologies). Samples were subjected to either immunoprecipitation with
5 mg RNA polymerase II CTD repeat YSPTSPS (phospho S2) antibody
(Abcam, Cambridge, UK) or control mouse IgGs o/n at 48C. For ChIP
primer-design, we first identified 2000–2500 bp upstream promoter
regions of candidate target genes by Ensembl Genome Browser (http://
www.ensembl.org/index.html). Then we screened the promoter
region for potential AP-1 binding sites by the use of ALLGEN-Promo
and selected appropriate primer pairs that amplify potential AP-1
binding sites. Subsequent PCR analysis of chipped DNA fragments was
done by mixing 2.5 mL sample, 2.5 mL 4 mM appropriate primer pairs,
10 mL HotStarTaq Mix (Qiagen) and applying the following protocol:
948C 10 min, [948C 1 min, 578C 30 s, 728C 1 min] ×33, 728C 10 min,
48C hold. The oligonucleotide primer sequence is given in Supplemen-
tary material online, Table S1.
Protein analysis
Protein expression was investigated by western blot analysis using 10–
40 mg of total protein. Tissue was homogenized, cells were pelleted.
Cell lysis was performed (Cell lysis buffer, Cell Signaling Technology,
Danvers, MA, USA) and protein electrophoresis initiated. Proteins
were transferred to polyvinylidene difluoride (PVDF) membranes,
blocked with 5% milk in TBS-Tween, and probed overnight at 48C with
the following primary antibodies: SMAD7 (rabbit anti-mouse, Invitrogen,
USA), PTEN (rabbit anti-mouse, Abcam), Foxo3a (rabbit anti-mouse,
Cell signaling Technology), phospho-AKT (ser) (rabbit anti-mouse, Cell
signaling Technology), AKT (rabbit anti-mouse, Cell signaling Technol-
ogy), phospho-ERK (44/42) (rabbit anti-mouse, Cell signaling Technol-
ogy), ERK (rabbit anti-mouse, Cell signaling Technology). Antibody
binding was visualized by chemiluminescence (Super-Signal West Pico
Chemiluminescent, Thermo Scientific, Rockford, IL, USA). Rabbit anti-
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Sigma-
Aldrich) was used as an internal loading control and for normalization
of protein quantification. Immunoblots were scanned and quantified
using ImageJ densitometry software. Recombinant OPN was purchased
at RnD systems (USA). The phosphoinositide-3-kinase (PI3-kinase)
inhibitor wortmannin was obtained from Sigma-Aldrich.
Scratch assay of primary fibroblasts
Primary cardiac fibroblasts isolated from WT animals were treated with
0, 0.5, 1, and2 mg/mLrecombinantOPN(RnDsytems,USA) immediately
after a scratch in the cell monolayer was generated with a 100 mL tip. In
certain experiments, miR-21 was silenced using locked nucleic acids
(LNAs) targeting miR-21 (LNA-21) and compared with cells transfected
with LNAs targeting a mismatch sequence (LNA-MM) for 72 h. The cells
were photographed at 0, 4, 8, 12, and 24 h with a Nikon Ti 90 microscope
(Germany). Subsequently, the migrated cell area was calculated.
microRNA/RNA isolation, miRNA/mRNA
reverse transcription–polymerase chain
reaction, and global transcriptome analysis
RNA isolation wasperformed with TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. For detection of miRNAs in samples,
different TaqMan miRNA assays (Applied Biosystems) were applied. The
small RNA molecule RNU-6B was amplified as a control. Reverse tran-
scription–polymerase chain reaction analysis was performed in an
ICycler (Bio- Rad). MiRNA expression analysis was performed in
hearts of OPN WT and KO mice subjected to Ang II infusion using the
Mouse Genome Wide microRNA 384-well qRT–PCR Array (Biocat,
Germany) according to the manufacturer’s instructions. Reverse tran-
scription was performed with total RNA using oligoDT primers
(Bio-Rad). Amplified cDNA was used as a template for quantitative
PCR. Reverse transcription–polymerase chain reaction analysis was per-
formed in an ICycler (Bio-Rad) with SYBR green mastermix. The specific
primers used in our study are depicted in Supplementary material online,
Table S1. For detection of OPN, we used primers provided by Qiagen
(Hilden, Germany) of undisclosed sequence.
microRNA target prediction
The miRNA databases and target prediction tools miRBase (http://
microrna.sanger.ac.uk/), PicTar (http://pictar.mdc-berlin.de/), and Tar-
getScan (http://www.targetscan.org/index.html) were used to identify
potential miRNA targets. We focused on targets predicted by at least
two prediction databases and containing a miR-21-8mer seed match in
the respective 3′UTR region.
Transfection assays
Transient liposomal transfection of small inhibitory RNAs (siRNAs) or
miRNAs was performed according to the manufacturers’ instructions.
Briefly, cells were split 1 day before transfection to reach 60–70%
confluence on the day of transfection. Specific siRNAs/miRNAs and
control siRNA/miRNA and Lipofectamine 2000 (Invitrogen) were
mixed separately and incubated for 5 min with Opti-MEM I media (Invi-
trogen). Complexes were added together and incubated for 20 min.
Media were changed to antibiotic-free media before the addition of lipo-
somal siRNA complexes (final concentration 150 nmol/L for siRNA and
100 nmol/L for miRNAs). Cells were incubated for 4 h before the media
were changed to fresh media. Silencing of proteins or miRNA targets was
monitored for 48 h (siRNA) or 72 h (miRNAs) after transfection by
western blot analysis.
Animal experiments
In the Ang II model of cardiac stress, OPN WT and OPN KO mice (each
n ¼ 6) were implanted with osmotic minipumps according to the manu-
facturers’ instructions (Alzet). Briefly, an incision was made in the mid-
scapular region, and an osmotic minipump (Alzet, model 2002; 0.5 mL/h
for 14 days) was implanted subcutaneously. The implanted minipumps
contained Ang II (Sigma-Aldrich) dissolved in water, and the infusion
rate was 1.5 mg/kg/day. Sham-operated mice underwent an identical sur-
gical procedure. Ang II minipump-implanted mice were either treated
with an LNA targeting a scrambled sequence or miR-21 (Exiqon) at
Day 0 and Day 7 (each dose 20 mg/kg) via intraperitoneal injection.
After 2 weeks, cardiac function and dimension were measured and the
hearts were removed for biochemical analysis. Cardiotropic OPN-
AAV9 or CTR-AAV9 vectors (for generation see Supplementary mater-
ial online, Methods) were injected by puncture of the retroorbital venous
plexus 2 weeks prior to implantation of osmotic minipumps. Sufficient
overexpression of OPN in vivo at the study endpoint was assessed
by western blot (rabbit anti-mouse OPN antibody, Abcam, UK).
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Immunostainings for inflammatory cell influx was performed using the
following primary antibody: monoclonal rat anti-mouse CD45 (BD Phar-
mingen, BD Biosciences, Santa Cruz, CA, USA).
Statistical analysis
Average data are presented as mean and standard deviation (SD) unless
otherwise stated. All statistical analyses were performed with the SPSS
package (SPSS Inc., Chicago, IL, USA) and GraphPad Prism software
(GraphPad Prism Software Inc., San Diego, CA, USA). Two-sided
P-values ,0.05 were considered statistically significant for all statistical
procedures used. For statistical comparison of two groups in in vitro ana-
lyses, we used an unpaired two-tailed Student t-test; for the comparison
of three or more groups, we used ANOVA followed by Tukey post-hoc
tests. Figures were generated by using Adobe Illustrator software.
Results
Ang II induces osteopontin expression in
cardiac cells and is elevated in humanswith
cardiac fibrosis due to aortic stenosis
First we treated cultured cardiac fibroblasts and cardiomyocytes with
Ang II and found increased OPN mRNA (cardiac fibroblasts, Figure 1A;
cardiomyocytes, Figure 1F) as well as enhanced secreted OPN in the
supernatant (cardiomyocytes, Figure 1G). In line with this observation,
myocardial tissue of patients with myocardial fibrosis related to aortic
stenosis (n ¼ 15) when compared with control patients (n ¼ 5)
showed increased levels of Collagen I and OPN (Figure 1H– I). Con-
comitant angiotensin receptor blocker (ARB) treatment in these
patients lowered elevated levels of OPN (Figure 1K).
Functional role of recombinant
osteopontin in cardiac fibroblasts
The results of the pre-clinical and clinical studies described earlier
about the potential role of OPN in cardiac fibrosis prompted us to
better understand the underlying mechanism. We thus next assessed
the functional role of recombinant OPN (rOPN) in cardiac fibroblasts
in vitro. OPN dose-dependently induced fibroblast migration as
assessed by a scratch assay (Supplementary material online, Figure
S1A–D and G). In addition, rOPN upregulated various pro-fibrotic
genes, including alpha smooth muscle actin (a-SMA) (Supplementary
material online, Figure S2A), connective tissue growth factor (CTGF)
(Supplementary material online, Figure S2B) and TGF-b (Supplemen-
tary material online, Figure S2C). Moreover, rOPN induced AKT phos-
phorylation by activation of phosphoinositide 3-kinase (PI3-kinase,
Supplementary material online, Figure S2E and F), which could be
blocked by the PI3-kinase inhibitor wortmannin (Supplementary ma-
terial online, Figure S2E and G).
Pro-fibrotic effects of Ang II-induced
osteopontin in vivo and in vitro
In order to assess the in vivo relevance of OPN with respect to fibrosis
development, we subjected OPN wild-type (WT) and OPN knock-
out (OPN KO) mice to chronic Ang II infusion via osmotic mini
pumps for 2 weeks (Figure 2). In both groups, Ang II increased
blood pressure (Supplementary material online, Table S2). Expected-
ly, we found that Ang II induced fibrosis in WT hearts as assessed by
Sirius red staining (Figure 2A–C ) and expression of the pro-fibrotic
genes collagen I and a-SMA (Figure 2G and H ). In contrast, in OPN
KO mice, fibrosis development as well as fibrotic gene expression
was strongly attenuated (Figure 2D–H ). Similarly, Ang II upregulated
various pro-fibrotic genes in cultured WT fibroblasts, including Col-
lagen I alpha 2, Collagen III, matrix metalloproteinase 2 (MMP2),
matrix metalloproteinase 9 (MMP9), and a-SMA (Supplementary
material online, Figure S3A–E), while there were no changes in
OPN KO fibroblasts (Supplementary material online, Figure S3F–H).
Ang II infusion in mice increased cardiomyocyte size in both groups
(WT and OPN KO mice, Figure 3A–E), but only increased heart
weight/body weight ratio in WT mice (Figure 3F), suggesting a
prominent anti-fibrotic effect of OPN deficiency specifically in
cardiacfibroblasts. Furthermore,Ang II inducedpro-survival andpro-
fibrotic signalling pathways in WT, but not in OPN KO hearts as
assessed by AKT, SMAD3, and ERK phosphorylation (Figure 3G–J).
Interestingly, in areas of increased collagen content (Sirius red stain-
ing), the expression of OPN was also increased, indicating a direct
role in fibrosis development (Figure 3K and L). In WT fibroblasts,
Ang II enhanced ERK phosphorylation as well as AKT phosphoryl-
ation (Supplementary material online, Figure S4A, B, F, and G). In add-
ition, Ang II led to the nuclear exclusion of Foxo3a, which is
associated with enhanced cellular survival (Supplementary material
online, Figure S4D, J, and K). None of these events occurred in OPN
KO fibroblasts (Supplementary material online, Figure S4C, E, H, I, L,
and M).
Pro-inflammatoryeffectsofAng II-induced
osteopontin in vivo and in vitro
In order to further elucidate the mechanism of fibrosis development
by Ang II, we assessed its potential pro-inflammatory role, since in-
flammation has been shown to be an important driver of fibrosis.
We found that Ang II upregulated the expression of the inflammatory
mediators interleukin-6 (IL-6), OPN, and macrophage chemoattract-
ant protein-1 (MCP-1) in WT, but not in OPN KO fibroblasts
(Figure 1A–E). In vivo, Ang II infusion induced the infiltration of
CD45+-leucocytes (Supplementary material online, Figure S5A–C)
as well as the mRNA expression of macrophage inflammatory
protein 2-alpha (MIP-2a), IL-1b, TNF-a, and MCP-1, while none of
thesechangesoccurred inOPNKOanimals (Supplementarymaterial
online, Figure S5D–G).
MiRNA expression analysis in osteopontin
wild-type and osteopontin knock out
animals
In order to further investigate the underlying mechanisms of fibrosis
development, we assessed the deregulation of miRNAs (miRs), a
classof short regulatoryRNAmolecules.AglobalmiRNAexpression
profiling in hearts of WT and OPN KO animals subjected to Ang II
infusion revealed a number of miRNAs to be deregulated
(Figure 2I). MiR-21 was one of the top upregulated miRNAs in WT
hearts compared with OPN KO hearts. The 10 most highly
up-regulated miRNAs of the array are shown in Supplementary ma-
terial online, Table S3. MiR-21 has previously been shown to serve as
master regulatorof fibrosis development.1,10 The resultsof the global
expression analysis were confirmed by independent qRT–PCR
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Figure 1 Ang II-induced inflammation and fibrosis: angiotensin II induces the mRNA expression of osteopontin (A), interleukin-6 (B), as well as
macrophage chemoattractant protein-1 (C ) in wild-type fibroblasts, while interleukin-6 (D) and macrophage chemoattractant protein-1 (E) levels
remain unchanged in osteopontin knockout fibroblasts in response to angiotensin II. Angiotensin II induces the mRNA expression of osteopontin in
vitro in cardiomyocytes (F) as well as the secretion of osteopontin in the cell-culture supernatant of cultured cardiomyocytes (G). n ¼ 5 independent
experiments. Expression of collagen I (H ), osteopontin (I), as well as miR-21 (J ) in cardiac biopsies of patients with myocardial fibrosis related to
aortic stenosis (n ¼ 15) compared with healthy control patients (n ¼ 5). Concomitant angiotensin-receptor blocker treatment lowers elevated
levels of osteopontin in biopsies of patients with myocardial fibrosis (K ).
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Figure 2 Ang II-induced fibrosis and miRNA expression in osteopontin wild type and knockout mice: Sirius red staining in paraffin-embedded
sections of cardiac tissue of osteopontin wild type mice following vehicle-infusion (2 weeks, PBS, A) and Ang II infusion (B) as well as quantification
of results (C ) and osteopontin knockout mice following vehicle-infusion (D) and Ang II infusion (E) as well as quantification of results (F ). Expression
of Collagen I (G) and alpha smooth muscle actin (a-SMA, H ) mRNA following Ang II or vehicle infusion. A global miRNA screen in hearts of osteo-
pontin wild type and osteopontin knockout mice following Ang II infusion (I ). MiR-21 expression in osteopontin wild type and knockout animals (J ).
n ¼ 6 animals per group and analysis.
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Figure3 Effects of osteopontin in vivo: wheat-germ agglutintin staining in osteopontin wild type (A and B) and knockout (C and D) mice to visualize
cell membranes of cardiomyocytes. Cardiomyocyte cell size was counted and quantified (E). Heart weight/body weight ratio in osteopontin wild
type and knockout mice (F). Downstream signalling pathways in vivo: phosphorylation of AKT (G and H ), SMAD2,3 (G and I ) and ERK (G and J )
in vivo. In areas of increased perivascular fibrosis (Sirus red staining, K ), osteopontin expression (brown staining) is also increased (L). n ¼ 6
animals per group and analysis.
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analysis in WT and OPN KO hearts (Figure 2J). In myocardial tissue of
patients with aortic stenosis compared with healthy control patients
miR-21 expression was also highly increased (Figure 1J). Intriguingly,
OPN expression displayed a close correlation with that of miR-21,
underlining its significance in human cardiac fibrosis (data not
shown, P, 0.01, r ¼ 0.5). In cultured cardiac fibroblasts isolated
from WT mice, Ang II also upregulated miR-21 expression (Supple-
mentary material online, Figure S6A), while the level of miR-21 was
unchanged in cardiac fibroblasts isolated from OPN KO animals
(Supplementary material online, Figure S6B). While OPN stimulated
enhanced migratory capacity of cardiac fibroblasts in a dose-
dependent way (Supplementary material online, Figure S1A–D
and G), miR-21 silencing blocked pro-migratory OPN effects (Sup-
plementary material online, Figure S1E, F, and H). We next aimed to
elucidate the potential transcriptional activation of miR-21 in
cardiac fibrosis related to Ang II. First, we found the expression of
primary miR-21 (pri-miR-21) to also be induced by Ang II in WT
cells, suggesting direct transcriptional activation (Supplementary ma-
terial online, Figure S6C). Transcriptional activation of miR-21 by Ang
II was further underlined by employing a miR-21 promoter primer
encompassing the AP-1 binding site after ChIP using an RNA poly-
merase II antibody (Supplementary material online, Figure S6D). It
was further shown that Ang II treatment induced binding of an
AP-1 oligonucleotide in electrophoretic mobility shift analysis in
WT fibroblasts, but not in OPN KO fibroblasts (Supplementary ma-
terial online, Figure S6E). MiR-21 expression (Supplementary material
online, Figure S1D) and AP-1 oligonucleotide binding (Supplementary
material online, Figure S6F) was also induced by rOPN. MiR-21
expression induced through rOPN could be lowered by PI3 kinase
inhibition with wortmannin, suggesting Akt to be upstream from
miR-21 (Supplementary material online, Figure S2H). Ang II-induced
miR-21 upregulation could be blocked by concomitant use of the
ARB losartan (Supplementary material online, Figure S3I). MiR-21
led to increased proliferation (Supplementary material online,
Figure S6G) and reduced apoptosis (Supplementary material online,
Figure S6H) of cardiac fibroblasts.
Adeno-associated viral vectors of
serotype-9-mediated overexpression of
osteopontin and miR-21 silencing in vivo
In order to further identify the pro-fibrotic role of OPN in vivo,
we generated cardiotropic OPN-AAV9 vectors for in vivo use
(Figure 4). OPN-AAV9 alone increased both OPN and miR-21 ex-
pression (Figure 4A–C). OPN-AAV9 together with concomitant
Ang II infusion significantly increased tissue fibrosis when compared
with control CTL-AAV9-treated (with Ang II) and sham-operated
animals (Figure 4D–F and I). Fibrosis development was highly attenu-
ated by use of an LNA targeting miR-21 (LNA-21, Figure 4G– I). The
reduction of fibrosis was more pronounced in CTL-AAV9-treated
animals than in OPN-AAV9-treated animals.
MiR-21 targets involved in increased
fibroblast survival in vivo and in vitro
We identified Phosphatase and tensin homolog (PTEN) and SMAD
family member 7 (SMAD7) as targets of miR-21 in WT animals
(Figure 5A–C) and WT cardiac fibroblasts (Supplementary material
online, Figure S7A, C, and E). Programmed cell-death protein 4
(PDCD4) was tested as an additional target, but could not be con-
firmed inour study(Figure5AandD foranimalsandSupplementaryma-
terial online, Figure S7A and D for cells). MiR-21 silencing in vivo by
LNA-21 treatment normalized the expression of PTEN and SMAD7
(Figure 5A–C). None of the aforementioned targets were regulated
in OPN KO animals (Figure 5E–H ) and OPN KO fibroblasts in vitro
(Supplementary material online, Figure S7B and F–H), most likely
related to unaltered levels of miR-21, further underlining the major
regulatory role of OPN with regard to fibrosis development.
Discussion
We here show that OPN is essential in transcriptional activation of
miR-21 in Ang II-induced cardiac fibrosis. The proposed mechanism
of Ang II action and the role of OPN with respect to cardiac fibrosis
are shown in Figure 6. The results are as follows: (i) OPN and miR-21
are increased in myocardial biopsies of patients with myocardial
fibrosis related to aortic stenosis; (ii) OPN KO mice are protected
from Ang II-induced cardiac fibrosis through a mechanism involving
AP-1-mediated miR-21 transcription and subsequent pro-fibrotic
action; (iii) miR-21 targets PTEN and SMAD7, thereby leading to
activation of WT fibroblasts; (iv) Ang II induces OPN expression in
WT fibroblasts; (v) OPN KO fibroblasts show impaired activation
and expression of pro-fibrotic genes, unaltered levels of miR-21 and
targets in response to Ang II; (6) Ang II leads to phosphorylation of
ERK and AKT as well as nuclear Foxo3a exclusion, culminating in
enhanced fibroblast survival; (vii) OPN is secreted from cardiomyo-
cytes by Ang II stimulation; (viii) recombinant/secreted OPN leads to
transcription of miR-21 through AP-1 activation, induces fibrotic
gene expression and survival of WT fibroblasts, partly through
PI3-kinase activation; (ix) in vivo overexpression of OPN by cardiotro-
pic OPN-AAV9 amplifies Ang II-induced cardiac fibrosis; (x) the use of
an LNA targeting miR-21 ameliorates Ang II-induced cardiac fibrosis.
Several experimental and clinical studies have highlighted the pro-
fibrotic role of OPN in cardiovascular disease.6,7,11 Plasma levels of
OPN are elevated in essential hypertension, and in patients with cor-
onary artery disease and re-stenosis.12– 14 OPN levels are predictive
of adverse cardiac events in patients with chronic stable angina.15
Kato et al.14 could show that pre-procedural OPN predicts re-
stenosis in patients undergoing percutaneous coronary intervention.
OPN has been implicated as a key factor in the development of ath-
erosclerosis,12– 18 and its expression was reported to be closely
related to arterial smooth muscle cell proliferation both in vitro and
in vivo.19,20 OPN-transgenic mice develop marked atherosclerosis.18
The results of our study confirm a major role of OPN in cardiovascu-
lar disease. Furthermore, we here unravel the underlying mechan-
isms of fibrosis development with regard to OPN. We show that
OPN is essential in activating the transcription factor AP-1, which
subsequently induces miR-21 transcription and regulation of anti-
fibrotic targets in Ang II-induced fibrosis. The transcription factor
AP-1 is a heterodimer composed of the subunits c-fos, the protein
families of c-Jun, activating transcription factor, and Jun dimerization
protein.1,21 The expression of AP-1 is induced by various cytokines
and growth factors and activates genes responsible for cellular differ-
entiation and proliferation.1,21 The transcription of fibrosis-asso-
ciated miRNAs, such as miR-21, is partly regulated by AP-1.1,22
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We also show that secreted/recombinant OPN induces a signifi-
cant increase of migration and proliferation of fibroblasts, thereby
promoting the further production of extracellular matrix and ultim-
ately interstitial fibrosis. This is due in part to the activation of
pro-survival phosphoinositide-3-kinase/Akt signalling as shown in
our study and by others.23–25 Furthermore, we show that OPN
itself activates AP-1, miR-21, and pro-fibrotic genes. These findings
are in line with previous data showing that OPN expression in skin
fibroblasts is responsible for inflammation-associated fibrosis.26
Delivery of OPN antisense oligodeoxynucleotides into mouse skin
wounds leads to accelerated healing and reduced granulation tissue
formation and scarring.26 Macrophage-derived platelet-derived
growth factor (PDGF)-BB seems to be responsible for the OPN
expression in wound fibroblasts.26 We show that Ang II induces
inflammation in WT fibroblasts and hearts of WT mice, while it is
absent in OPNKO fibroblasts andmice.Ang II treatment is associated
with enhanced fibroblast survival in vitro by the regulation of PTEN
through miR-21. Reduced PTEN levels result in an activation/phos-
phorylation of AKT and a downstream inactivation of Foxo3a by
nuclear exclusion, thus promoting fibroblast survival.27 SMAD7
was identified as an additional target of miR-21, thereby promoting
the fibrosis process. We show that Ang II activates the TGF-b
Figure 4 MiR-21 expression in mice following cardiotropic osteopontin-AAV9 injection (A) as well as osteopontin protein expression in hearts
(B and C) compared withCTL-AAV9. Sirius red staining inparaffin-embedded sectionsof cardiac tissue of sham-operated mice (D), mice subjected to
CTL-AAV9 and Ang II (E), osteopontin-AAV9 and Ang II (F), CTL-AAV9 and Ang II as well as locked-nucleic acid treatment targeting miR-21
(LNA-21, G), osteopontin-AAV9 and Ang II as well as LNA-21 (H ), and quantification of results (I ). n ¼ 5 animals per group and analysis.
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Figure5 miR-21 targets inosteopontin wild typeandknockoutmice: Proteinexpressionaswell as densitometric quantificationofPTEN(A andB),
SMAD7 (A and C), and PDCD4 (A and D) in wild type mice subjected to Ang II and locked-nucleic acid treatment targeting miR-21 (LNA-21) or
control mismatch LNA (LNA–MM) treatment. Protein expression as well as densitometric quantification of PTEN (E and F), SMAD7 (E and G),
and PDCD4 (E and H ) in osteopontin knockout mice subjected to Ang II infusion. n ¼ 6 animals per group and analysis.
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signalling pathway. The interrelation between Ang II and TGF-b is
established.28 TGF-b binds to type II receptor, which activates the
type I receptor kinase, which, in turn, phosphorylates the receptor-
regulated SMADs SMAD2 and SMAD3.The SMAD complexes trans-
locate to the nucleus and function as transcriptional regulators of
target genes. The inhibitory SMAD7 binds to activated type I recep-
tor, thereby preventing phosphorylation of SMAD2/3, or recruits the
ubiquitin ligases Smurf1 and Smurf2 to induce proteasomal degrad-
ation of the receptor complexes.29–30
Intriguingly, we also found OPN and miR-21 to be increased in myo-
cardial biopsies of patients with aortic stenosis. Moreover, miR-21 and
OPN showed a strong degree of correlation. Elevated levels of OPN
can be lowered by ARB treatment in humans. This is in line with previ-
ous results by our group.31 Similarly, miR-21 and OPN expression in
cultured fibroblasts can be blocked by pre-treatment with the ARB
losartan. These findings are well in line with recent experimental
data. In a study involving male Japanese white rabbits fed on a high-
cholesterol diet, treatment with olmesartan decreased macrophage
Figure 6 Proposed scheme of angiotensin II-induced osteopontin expression: angiotensin II leads to the expression of osteopontin in cardiac
fibroblasts, which induces AP-1-mediated transcription of miR-21. Mature miR-21 targets and down-regulates PTEN, which subsequently leads
to phosphorylation of AKT and nuclear exclusion of FOXO3a. In addition, miR-21 targets SMAD7, which results in phosphorylation of ERK. In car-
diomyocytes, angiotensin II leads to the secretion of osteopontin, which induces the aforementioned mechanisms. Moreover, secreted osteopontin
activates the PI3-kinase pathway as well as AKT phosphorylation. Taken together these mechanisms results in fibroblast survival and deposition of
extracellular matrix (ECM).
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accumulation and OPN expression in aortic valve leaflets.32 Knock-
down of OPN in vascular smooth muscle cells by siRNA reduced
Ang II-induced mediators of inflammation.33 These results indicate
that Ang II-induced inflammation and subsequent fibrosis is at least
in part mediated by OPN. Our results confirm a regulatory effect of
ARB treatment on OPN.
OPN deficiency reduced the number of infiltrating CD45+-
leucocytes in response to Ang II-infusion in our study. The import-
ance of OPN in leucocyte chemotaxis was exemplified by the
impaired recruitment of OPN 2/2 neutrophils in experimental
colitis, which was restored after the administration of exogenous
OPN.34 The increased level of OPN would support a role for osteo-
pontin in an autocrine feedback loop, which could potentiate the
disease process by promoting the further accumulation of mono-
cytes and macrophages to the site of inflammation with subsequent
increase in fibrosis.
Intriguingly, AAV9-mediated overexpression of OPN in vivo
specifically in the heart using cardiotropic OPN-AAV9 further
enhanced Ang II-related fibrosis underlining the in vivo significance
of OPN with regard to fibrosis development. Our results are in
line with previous studies using adenoviral constructs to overexpress
OPN in hepatocytes with respect to liver fibrosis.35
We were previously able to show that in cardiac fibrosis in re-
sponse to cardiac pressure overload, miR-21 is specifically enriched
in cardiac fibroblasts promoting fibroblast survival and growth factor
secretion.10 In our study, miR-21 silencing in vivo by using an LNA tar-
geting miR-21 prevented the development of Ang II-induced cardiac
fibrosis. Supplementary material online, Table S3 lists the 10 most
highly upregulated miRNAs in our array. For instance miR-181a
was also among the top deregulated miRNAs. MiR-181a has previ-
ously been shown to be a TGF-b regulated miRNA.36 Therefore, it
cannot be entirely excluded that other miRNAs also contribute to
OPN-mediated fibrosis. However, we believe that our data clearly
demonstrate a pathophysiological link between deregulated OPN
expression, miR-21 induction, and cardiac fibrosis development.
In conclusion, we show that Ang II-induced cardiac fibrosis is
mediated by activation of the transcription factor AP-1 and subse-
quent miR-21 regulation. MiR-21 targets the anti-survival and anti-
fibrotic targets PTEN and SMAD7, ultimately resulting in fibroblast
proliferation. OPN KO mice are protected from Ang II-induced
cardiac fibrosis through impaired activation of AP-1 and miR-21.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Unique coronary artery anomaly: three separate coronary artery
ostia within one coronary sinus
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A 69-year-old patient was presented at our
cardiac care unit with acute inferior infarction,
for which she underwent primary PCI.
Cardiac catheterization revealed unique coron-
ary artery anatomy, with an aberrant left main cor-
onary artery (LMCA), and a septal branch both
deriving from the right sinus Valsalva, but with sep-
arate ostia from the right coronary artery (Panels A
and B; Supplementary material online, Videos S1
and S2). The LMCA passes the pulmonary artery
anteriorly, after which it bifurcates into the left anterior descending artery and the ramus circumflex. A septal branch passes in
between the aorta and the right ventricular outflow tract. Cardiac CT confirmed this coronary arterial course (Panel C).
The origin of the LMCA from the right aortic sinus of Valsalva is the least common coronary anomaly (incidence: 0.15%), and is notorious
for its malign course between the great vessels. A benign course (LMCA anterior to the pulmonary trunk), as was the case in our patient,
remains even more rare. Indeed, the fact that three coronary arteries derive from a single sinus, but with three separate ostia seems unique.
The benign course of coronary anomaly explains the fact that our patient had remained without symptoms throughout her life, and pre-
sented with acquired ischaemic heart disease at the age of 69. There is no intention to correct her anomaly as no harm is expected from it in
the future.
Supplementary material is available at European Heart Journal online.
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